The U.S. Food and Drug Administration (FDA) has approved 50 new molecular entities in 2024, with 24 designated as first-in-class therapies. This trend is expected to continue in 2025, with several first-in-class drugs set to be approved. These innovative treatments offer new approaches to challenging diseases, including schizophrenia, metabolic-associated steatohepatitis, and rare genetic disorders. Forecast…
Singapore has made significant strides in becoming a global biotech hub, with a growing startup ecosystem and a focus on research and development. The country has invested heavily in the life sciences sector, with billions of dollars poured into the industry over the past two decades. This has led to the emergence of several biotech…
A recent report by Clarivate highlights several blockbuster drugs poised to revolutionize the biotech industry. These treatments, expected to generate over $1 billion in sales, include CagriSema for type 2 diabetes, Awiqli for long-acting insulin, Cobenfy for schizophrenia, and several others. As these drugs make their way to market, they are expected to transform the…
India’s biotech sector is experiencing rapid growth, with the country’s bio-economy expanding from $10 billion in 2015 to $130 billion in 2024. The sector is expected to continue its growth, reaching $300 billion by 2030. Top biotech companies in India, such as Bugworks Research, Biocon, and Eyestem, are making significant contributions to the sector, developing…
Labiotech has curated a list of biotech movies that explore the intersection of science, technology, and humanity. From eugenics to genetic engineering, these films delve into the possibilities and consequences of emerging biotech trends. As the biotech industry continues to advance, these movies serve as a thought-provoking reflection on the potential implications of our actions….
The biotech industry is expected to see significant advancements in 2025, with several companies working on innovative therapies for various diseases. Anavex Life Sciences, Candid Therapeutics, Enterprise Therapeutics, Jazz Pharmaceuticals, Life Biosciences, Ovid Therapeutics, Skye Bioscience, TG Therapeutics, Wave Life Sciences, and Quotient Therapeutics are among the companies to watch in 2025. These companies are…
A looming patent cliff threatens to disrupt the pharmaceutical industry, with over $200 billion in annual revenue at risk through 2030. However, this presents a significant opportunity for biosimilar developers to capitalize on the transition to more affordable treatments. Several companies, including Alvotech, Biocon Biologics, Celltrion, Formycon, and Samsung Bioepis, are already making strides in…
The holiday season is upon us, and with it comes the opportunity to gift our loved ones something unique and meaningful. Biotechnology-themed gifts are gaining popularity, and this article highlights some of the most interesting and innovative ideas. From glow-in-the-dark mushrooms to DIY biology kits, these gifts not only showcase the wonders of biotechnology but…
The article highlights six antisense oligonucleotide companies leading the way in this emerging field. These companies, including Ionis Pharmaceuticals, Isarna Therapeutics, Regulus Therapeutics, Sarepta Therapeutics, Secarna Pharmaceuticals, and Wave Life Sciences, are developing innovative treatments for various diseases. The global antisense oligonucleotides market is projected to grow significantly, driven by the ability of these treatments…
MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression. Several companies are advancing candidates relying on miRNAs in 2024, with potential applications in disease diagnosis and treatment. Companies such as aceRNA Technologies, ARTHEx Biotech, and Transcode Therapeutics are developing innovative miRNA-based therapeutics for various diseases, including cancer, cardiovascular…
